NTHI NeOnc Technologies Holdings Inc.

Subscribe to $NTHI

NeOnc Technologies Holdings Inc.

Subscribe to $NTHI

$NTHI

Biotechnology: Pharmaceutical Preparations

Health Care

IPO Year:

Exchange: NASDAQ

Recent Analyst Ratings for NeOnc Technologies Holdings Inc.

Date	Price Target	Rating	Analyst

See more ratings

NeOnc Technologies Holdings Inc. Press Releases

Fastest customizable press release news feed in the world

NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets
-- 176 Patents Issued and Outstanding Reinforces NeOnc's Competitive Position -- CALABASAS, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a biopharmaceutical company focused on the development of novel oncology and neurology therapeutics, today announced that its global patent portfolio totals 176, reinforcing its competitive position. The Company's IP portfolio, covering its core pipeline, currently comprises 126 issued patents - 29 in the United States and 97 internationally; and 50 pending patents - 19 in the United States and 31 internationally. NeOnc's expanding IP portfolio reflects its innovation engine as well as its comm
4/15/25 8:05:00 AM ET
$NTHI
Biotechnology: Pharmaceutical Preparations
Health Care
NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September
-- Trial Read-Out Data Expected in Early 2026 -- CALABASAS, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced that it expects full enrollment in its Phase 2a clinical trial for its lead therapeutic candidate, NEO100-01 in September. Only six patients remain to complete the trial's 25-patient enrollment target. This landmark trial, for which read-out data is expected in early 2026, investigates NEO100, a proprietary, highly purified version of perillyl alcohol, delivered intranasally, a non-invasive me
4/14/25 8:05:00 AM ET
$NTHI
Biotechnology: Pharmaceutical Preparations
Health Care
NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New President
CALABASAS, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced that Executive Chairman Amir Heshmatpour has been appointed to serve as President of the Company. Heshmatpour will retain his role as Executive Chairman, while taking on day-to-day leadership responsibilities to accelerate the Company's strategic and clinical initiatives. "Amir's appointment as President reflects our commitment to strong, visionary leadership as NeOnc advances its clinical programs," said Dr. Thomas Chen, CEO of NeOnc. "His e
4/10/25 8:05:00 AM ET
$NTHI
Biotechnology: Pharmaceutical Preparations
Health Care
NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy
CALABASAS, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced that its Phase I clinical trial of NEO212, a development-stage bio-conjugated therapeutic for brain cancer, is nearing full enrollment. The final cohort (Cohort 5) is expected to complete the study's dosing protocol, marking a major milestone in the drug's development timeline. NEO212 is a proprietary conjugation of temozolomide (TMZ)—the current standard-of-care chemotherapy for malignant gliomas—and perillyl alcohol (POH), a naturally occur
4/8/25 4:05:00 PM ET
$NTHI
Biotechnology: Pharmaceutical Preparations
Health Care
NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas
WESTLAKE VILLAGE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ Global Market: NTHI), a clinical-stage medical biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to perillyl alcohol (NEO100™) for the treatment of pediatric-type diffuse high-grade gliomas, a serious and life-threatening condition affecting children and adolescents. The designation, issued under Section 529(a)(3) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), recognizes the urgent need for treatment options for pediatric-type diffuse high-grade gliomas. The FDA's decision is based on f
3/31/25 8:05:00 AM ET
$NTHI
Biotechnology: Pharmaceutical Preparations
Health Care

NeOnc Technologies Holdings Inc.

Recent Analyst Ratings for NeOnc Technologies Holdings Inc.

NeOnc Technologies Holdings Inc.

Recent Analyst Ratings for NeOnc Technologies Holdings Inc.

NeOnc Technologies Holdings Inc. SEC Filings

SEC Form SCHEDULE 13D filed by NeOnc Technologies Holdings Inc.

SEC Form D filed by NeOnc Technologies Holdings Inc.

NeOnc Technologies Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

NeOnc Technologies Holdings Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

NeOnc Technologies Holdings Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Amendment: CFO Garnett Keithly disposed of 687 shares, exercised 13,438 in-the-money shares at a strike of $12.00 and sold $164,426 worth of shares (6,616 units at $24.85) (SEC Form 4)

Amendment: Director Heshmatpour Amir F disposed of 3,996 shares, exercised 78,125 in-the-money shares at a strike of $12.00 and sold $955,941 worth of shares (38,464 units at $24.85) (SEC Form 4)

Amendment: COO Walters Patrick disposed of 1,231 shares, exercised 24,063 in-the-money shares at a strike of $12.00 and sold $294,432 worth of shares (11,847 units at $24.85) (SEC Form 4)

Amendment: Director Chiang Ming-Fu (Alan) was granted 50,000 shares, disposed of 5,994 shares, exercised 117,188 in-the-money shares at a strike of $12.00 and sold $1,433,912 worth of shares (57,696 units at $24.85), increasing direct ownership by 15% to 390,216 units (SEC Form 4)

Amendment: CEO Chen Thomas C disposed of 4,076 shares, exercised 79,688 in-the-money shares at a strike of $12.00 and sold $975,055 worth of shares (39,233 units at $24.85) (SEC Form 4)

CFO Garnett Keithly disposed of 687 shares (SEC Form 4)

CEO Chen Thomas C disposed of 4,076 shares (SEC Form 4)

Director Giannotta Steven L. was granted 50,000 shares, increasing direct ownership by 31,250% to 50,160 units (SEC Form 4)

Director Delshad Jim was granted 50,000 shares, increasing direct ownership by 31,250% to 50,160 units (SEC Form 4)

Director Chiang Ming-Fu (Alan) disposed of 5,994 shares and was granted 50,000 shares, increasing direct ownership by 15% to 390,216 units (SEC Form 4)

NeOnc Technologies Holdings Inc. Press Releases

Fastest customizable press release news feed in the world

NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets

NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September

NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New President

NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy

NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas